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Abstract
RNA-based arbitrarily primed PCR (RAP-PCR) was used to identify sequences in CHO K1 cells that were differentially
expressed upon methotrexate incubation during the development of resistance to this drug. Ten different RAP products were
isolated, cloned and sequenced. Among these, we identified one sequence that showed 84% identity with the nucleotide
sequence of rat cytochrome c oxidase subunit II, and 90% identity with the amino acid sequence of this protein. This RAP
fragment was up-regulated in a dose- and time-dependent manner. The overexpression of cytochrome c oxidase subunit II
mRNA as a result of methotrexate incubation was corroborated by quantitative RT-PCR and Northern blot analysis.
Incubation of cells with sodium azide, a specific cytochrome c oxidase inhibitor, decreased the number of resistant colonies
after methotrexate treatment. Thus, overexpression of cytochrome c oxidase is involved in the development of resistance to
methotrexate. These results suggest that sodium azide may be used as a modulator in chemotherapy with
methotrexate. ß 2000 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Methotrexate (MTX) is widely used as a chemo-
therapeutic agent, alone or in combination, for its
property to inhibit dihydrofolate reductase
(DHFR). This enzyme catalyzes the synthesis of pu-
rines, thymidylate and glycine, and is therefore
needed for the synthesis of DNA, thus its use as a
target in cancer chemotherapy. Even though MTX
treatment is very e¡ective, it has the drawback of
originating drug resistance, which is manifested by
the development of resistant clones that present de-
creased transport of this drug [1], mutation of the
DHFR protein [2], or gene ampli¢cation at the dhfr
locus [3,4]. One way of improving MTX performance
would be the administration of resistance modulators
that could decrease the frequency of appearance of
surviving clones. With this in mind our aim was ¢rst
to identify genes involved in the development of re-
sistance to this drug. To do so we applied the RNA-
based arbitrarily primed PCR technique (RAP-PCR)
to pinpoint genes that were di¡erentially expressed
upon MTX treatment. This technique has been
used successfully for the detection or isolation of
di¡erentially expressed genes such as cyclin A, osteo-
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nectin, TGF-L1-repressed transcript 1 in cells in
which growth was arrested by TGF-L1 [5] ; neural
membrane protein 35 in the developing rat sciatic
nerve [6] ; DOC2 in ovarian cell cultures [7] ; and
several genes that are up- or down-regulated after
neuronal di¡erentiation induced by retinoic acid,
such as CD59, human transcription factor SUPT4H
and human cadherin [8].
In this study we show that cytochrome c oxidase
subunit II (COX II) is overexpressed in MTX-treated
cells, and that by using an inhibitor of this enzymatic
activity in combination with MTX, the development
of colonies resistant to this chemotherapeutic agent is
markedly decreased.
2. Materials and methods
2.1. Cell culture
Conditions for the monolayer culture of Chinese
hamster ovary (CHO) cells were as described previ-
ously [9]. CHO K1 cells were grown in Ham’s F12
medium supplemented with 7% fetal calf serum
(FCS, above two from Gibco) and maintained at
37‡C in a humidi¢ed 5% CO2-containing atmos-
phere.
To obtain RNA from MTX-treated cells, 500 000
CHO K1 cells were plated on 100 mm diameter
dishes in 10 ml selective medium lacking hypoxan-
thine, thymidine and glycine (3GHT) supplemented
with 5% dialyzed fetal calf serum, and after 18^20 h
the cells were treated with di¡erent concentrations of
MTX for di¡erent periods of time.
In the experiments directed to assess the cytotox-
icity of MTX, alone and in combination with NaN3,
3000 cells were incubated in 35 mm diameter dishes
with the indicated concentrations of the drugs. After
1 week the surviving colonies were stained with crys-
tal violet, counted and the viability expressed as the
percentage of cell survival with respect to control
cells.
To analyze the e¡ect of NaN3 on MTX resistance,
cells were incubated with di¡erent concentrations of
NaN3 in combination with 3U1037 M MTX and
after 1 week, NaN3 was removed maintaining the
MTX pressure until the formation of resistant colo-
nies, usually 3 weeks.
2.2. RNA obtention
After di¡erent times of MTX treatment, K1 cells
were collected in 1 ml of Ultraspec RNA Reagent
(Biotecx), and total RNA was extracted following
the indications provided by the manufacturer.
Twenty Wg of total RNA were treated with 4 U
RNase-free DNase I (Boehringer Mannheim) for 30
min at 37‡C in a DNase bu¡er (MgCl2 10 mM, Tris-
HCl 10 mM, pH 8.0) containing 40 U RNasin
(Promega). After RNA precipitation, the pellet was
resuspended in 20 Wl diethylpyrocarbonate (DEPC)
treated water.
2.3. cDNA synthesis
One Wg of DNase-treated RNA was used for the
¢rst strand synthesis of cDNA. Before the reaction
the RNA was heated at 70‡C for 10 min in DEPC-
treated water and immediately placed on ice. Then
the rest of the components of the reaction mixture
were added and incubated at 37‡C for 1 h, followed
by 95‡C for 10 min to inactivate the reverse tran-
scriptase. The composition of the reaction mixture,
in a volume of 50 Wl, was: 200 WM dNTPs (Sigma),
10 mM dithiothreitol, 40 U RNasin, 100 U reverse
transcriptase M-MLV (BRL), 75 mM KCl, 3 mM
MgCl2, 50 mM Tris-HCl, pH 8.3, and 1 WM (0.33




Second strand cDNA synthesis was also initiated
by arbitrarily priming by adding 3 Wl of ¢rst strand
reaction to 22 Wl PCR mixture containing 200 WM
dNTPs, 1.5 mM MgCl2, 50 mM KCl, 20 mM Tris-
HCl, pH 8.0, 1 U Taq polymerase (BRL), 2.5 WCi
[K-32P]dATP, and 1 WM primer Dmex3-3P. The prim-
er added in this step was the same as that used for
the ¢rst strand synthesis. The reaction mixture was
subjected to one low stringency cycle: 94‡C for 5 min
to denature the cDNA, 40‡C for 5 min to anneal the
primer, and 72‡C for 5 min for DNA synthesis. This
was followed by 40 high stringency cycles: 94‡C for
1 min, 60‡C for 1 min and 72‡C for 2 min, with a
¢nal step of 72‡C for 7 min.
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2.5. Gel electrophoresis
Three Wl of each PCR reaction were added to 10 Wl
of loading bu¡er containing 80% formamide, heated
at 65‡C for 15 min and 3 Wl of each sample were
loaded on a sequencing gel (6% polyacrylamide/bis-
acrylamide 19:1, 8 M urea, 1 mM EDTA, 45 mM
Tris/borate pH 8), and electrophoresed at 60 W. The
gel was dried and the radioactive bands were visual-
ized by autoradiography.
2.6. Isolation of RAP products
Di¡erentially ampli¢ed RAP products were ex-
cised from the gel and eluted into 50 Wl TE bu¡er
(10 mM Tris-HCl, pH 7.5, 1 mM EDTA) for 2 h at
65‡C. A 5 Wl aliquot was then used to reamplify the
RAP products in 50 Wl of PCR reaction using 500 ng
of Dmex3-3P primer. To obtain speci¢c PCR prod-
ucts in this step, the reaction mixture was separated
in two phases by a solid para⁄n wax layer (melting
temperature = 59^60‡C, Fluka), which prevents com-
plete mixing of PCR reactants until the reaction has
reached a temperature at which non-speci¢c anneal-
ing of primer to non-target DNA is minimized. The
lower solution contained the MgCl2, the dNTPs, the
primer and half of the bu¡er, and the upper solution
contained the 5 Wl RAP product, the Taq enzyme
and the remaining bu¡er. PCR was performed for
40 cycles, after a 1 min denaturation at 94‡C; each
cycle consisted of denaturation at 92‡C for 1 min,
primer annealing at 60‡C for 1 min, and primer ex-
tension at 72‡C for 2 min. The PCR products were
gel puri¢ed.
2.7. Cloning and sequencing of RAP products
RAP products were phosphorylated with T4 poly-
nucleotide kinase, treated with Klenow polymerase,
and ¢nally cloned into pcDNA3 vector at the EcoRV
site. Clones were sequenced by the Sanger method
using Taq polymerase and pcDNA3 for oligonucleo-
tide labeled with 32P. The sequence of the pcDNA3.-
for primer was 5P-GGGCGGTAGGCGTGTACGG-
T-3P which hybridized to the pcDNA3 vector in the
5P of its polylinker region.
Sequence comparisons were performed by using
the Fasta analysis within the GCG package
program (Madison, WI), using GenBank as the data-
base.
2.8. mRNA analysis by RT-PCR
RNA analysis was performed by quantitative RT-
PCR as described previously [10^12]. [K-32P]dATP
was used in the PCR to produce a radioactive prod-
uct that could be detected with great sensitivity dur-
ing the exponential phase of the reaction. The same
cDNA preparation was ampli¢ed with primers for
cox II and for adenosyl phosphoribosyl transferase
(aprt). APRT mRNA served as an internal control
for reverse transcription and for PCR.
Total mRNA from CHO K1 cells treated in the
absence or in the presence of MTX extracted as de-
scribed above was used to determine the mRNA lev-
els for COX II.
cDNA was synthesized in a 20 Wl reaction mixture
containing 1 Wg of RNA (in DEPC-treated water),
125 ng of random hexamers (Promega), 10 mM di-
thiothreitol, 20 units of RNasin (Promega), 500 WM
dNTPs (Sigma Qu|¤mica), 4 Wl of 5URT bu¡er and
200 units of M-MLV reverse transcriptase (above
two from BRL). The reaction mixture was incubated
at 37‡C for 60 min. Five Wl of the cDNA mixture
was used directly for PCR ampli¢cation.
PCR reactions were typically carried out as fol-
lows. A standard 50 Wl mixture contained 5 Wl of
the cDNA mixture, 4 Wl of 10UPCR bu¡er (Mg2-
free), 1.5 mM MgCl2, 200 WM dNTPs, 2.5 WCi of
[K-32P]dATP (3000 Ci/mmol, Amersham), 1 unit of
Taq polymerase (BRL) and 500 ng of each of four
primers. The primers used were: 5P-ATCGCCCTC-
CCATCCCTACG-3P and 5P-TCATGAGTGCAAG-
ACGTCTT-3P for cox II and 5P-CGCAGTTTCCC-
CGACTTCCC-3P and 5P-GGCAGCGCACATGG-
TTCCTC-3P for aprt, which was used as an internal
control. The primers to amplify COX II mRNA were
designed after PileUp analysis (GCG package) of
the rat and human sequences. They were chosen
within the most conserved regions, and after RT-
PCR using either human (K562) or hamster (CHO
K1) cells, originated fragments of the same length
(264 bp). The reaction mixture was separated in
two phases by the solid para⁄n wax layer method
described above. PCR was performed for 25 cycles,
after a 1 min denaturation at 94‡C; each cycle con-
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sisted of denaturation at 92‡C for 30 s, primer an-
nealing at 55‡C for 1 min, and primer extension at
72‡C for 1 min. Five Wl of each PCR sample was
electrophoresed in a 5% polyacrylamide gel. The
gel was dried and the radioactive bands were visual-
ized by autoradiography.
Results were quanti¢ed by image analysis using
the NIH Image program v. 1.61. Changes in COX
II mRNA levels were calculated from the ratio of the
intensities between the cox II and the aprt signals.
2.9. mRNA analysis by Northern blot
COX II mRNA levels were also analyzed by
Northern blot using a homologous probe. The ham-
ster probe was obtained by RT-PCR using total
RNA from CHO K1 cells. The primers used in
the PCR were 5P-CATGATCACGCCCTCATAA-
TC-3P and 5P- GACGATGGGCATGAAACTGTG-
3P, complementary to the human cox II sequence.
PCR was performed at two di¡erent annealing tem-
peratures; for the ¢rst 7 cycles at 57‡C, and for the
remaining 33 cycles at 52‡C. After 1 min denatura-
tion at 94‡C, each cycle consisted of denaturation at
92‡C for 30 s, primer annealing for 1 min, and prim-
er extension at 72‡C for 1 min 15 s, with a ¢nal step
at 72‡C for 5 min to complete the synthesis of the
PCR fragments. The ampli¢ed fragment was 560 bp
in length. The probe was then gel-puri¢ed and la-
beled with [K-32P]dATP using the Prime-a Gene la-
beled System (Promega).
Forty Wg of total RNA from either CHO K1 con-
trol cells or from cells treated with MTX at di¡erent
times and concentrations were run in a 1% formal-
dehyde-agarose gel and transferred to a Zeta-Probe
GT blotting membrane (Bio-Rad) using 50 mN
NaOH as the transfer solution. The hybridization
was performed at 68‡C overnight using the Express-
Hyb Hybridization Solution (Clontech), 100 Wg so-
nicated herring sperm DNA/ml and the radioactive
probe (2U106 cpm/ml). The blots were washed three
times in 2USSC plus 0.05% SDS for 10 min each at
room temperature, once in 1USSC plus 0.05% SDS
for 10 min at room temperature, once in 1USSC
plus 0.05% SDS for 20 min at 50‡C and once in
0.5USSC for 20 min at 50‡C. After washing, the
membrane was exposed to X-ray ¢lms. Results
were quanti¢ed by image analysis using the NIH
Image program (v. 1.61). COX II mRNA levels
were expressed as fold-increase of the control value
corresponding to untreated cells.
3. Results and discussion
In order to identify genes involved in the develop-
ment of resistance to MTX, we have applied the
RAP-PCR methodology on total RNA obtained
from CHO K1 cells treated with MTX. The cell in-
cubations were performed for 5 or 10 days with con-
Fig. 1. RAP ¢ngerprints of total RNA from CHO K1 cells
treated with MTX. K1 cells were incubated with the indicated
concentrations of MTX, and after the indicated periods of time
total RNA was extracted. One Wg of DNase-treated total RNA
was used in the RAP-PCR with arbitrarily chosen primer
Dmex3-3P. Three Wl of the PCR products were resolved in a de-
naturing polyacrylamide gel. The gel was dried and exposed to
RX ¢lms. Arrows indicate some of the di¡erentially ampli¢ed
products between the control RNA (CNT) and RNAs from
MTX-treated cells. Arrow No. 6 corresponds to the RAP prod-
uct identi¢ed as COX II.
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centrations of MTX ranging from 9U1038 M to
2U1037 M, which allow the appearance of resistant
colonies [13]. We prepared RNA from cells incu-
bated for these short periods of time with the aim
of detecting messages that were di¡erentially ex-
pressed during the process of development of resis-
tance to MTX rather than analyzing the di¡erences
in mRNA expression once the resistance had been
established.
Equal amounts of RNA obtained after each treat-
ment were subjected to the RAP-PCR methodology
using the arbitrary primer Dmex3-3P both in the re-
verse transcriptase reaction and in the PCR. In the
PCR 2.5 WCi of [K-32P]dATP was added to the reac-
tion mixture to obtain radiolabeled RAP fragments.
Samples (3 Wl) of the PCR were resolved in a dena-
turing gel, and after autoradiography, ten RAP
products which were di¡erentially expressed could
be observed (Fig. 1). Each RNA was ¢ngerprinted
in duplicate, obtaining similar patterns of di¡erential
expression. These di¡erences in expression depended
on the time and the concentration of the MTX used
in the cell incubation. Slices from the gel correspond-
ing to these RAP products were extracted in TE, and
5 Wl were used in an additional PCR to amplify the
product for further ligation to the pcDNA3 vector.
The sequences of the RAP products were compared
to the GenBank database using the Fasta analysis
within the GCG package (Genetic Computer Group,
Version 9.1, Madison, WI).
One of these hamster sequences showed a high
degree of identity to the RNA for COX II from
rat. This sequence corresponded to a RAP fragment
(arrow No. 6 in Fig. 1) which was overexpressed in a
time- and dose-dependent manner upon MTX treat-
ment. The identity was 84% when comparing the nu-
cleotide sequences, and 90% if the sequences of the
protein were compared, given the occurrence of syn-
onymous codons between the hamster and rat se-
quences.
To corroborate that COX II is overexpressed upon
MTX treatment, we used quantitative RT-PCR to
analyze COX II mRNA levels in CHO K1 cells in-
cubated with di¡erent concentrations of MTX during
di¡erent periods of time. As an internal control, we
used the APRT mRNA levels, the expression of
which did not change in the presence of MTX. The
levels of COX II mRNA increased after MTX incu-
bation in a time- and dose-dependent manner (Fig.
2), reaching 2.6-fold overexpression in the presence
of 2U1037 M MTX, a concentration that results in
the appearance of resistant colonies [13]. The results
of the RT-PCR were con¢rmed by Northern blot
analysis using as a probe a PCR fragment of 560
bp corresponding to the hamster COX II mRNA.
This homologous probe was obtained as described
in Section 2. In these conditions, we observed an
increase in the levels of COX II mRNA with the
MTX treatment, reaching a 6-fold overexpression
in the presence of 2U1037 M MTX (Fig. 2).
To attest the involvement of COX, the last enzy-
matic activity in the mitochondrial respiratory chain,
in the development of resistance to MTX, we incu-
Fig. 2. COX II mRNA levels by RT-PCR in CHO K1 cells
upon MTX incubation (left). One Wg of total RNA, obtained
under the same conditions as described in Fig. 1, was subjected
to quantitative RT-PCR to determine the levels of COX II
mRNA after MTX treatment for the times and concentrations
indicated in the ¢gure. PCR was performed using speci¢c prim-
ers for cox II and aprt, the latter used as an internal control.
The top panel corresponds to a representative autoradiography
of the PCR products; quanti¢cation of the bands is shown in
the bottom panel. COX II mRNA levels by Northern blot anal-
ysis in CHO K1 cells upon MTX incubation (right). Forty Wg
of total RNA either from CHO K1 control cells or from cells
treated with MTX at the indicated times and concentrations
were subjected to Northern blot analysis with a homologous
probe to determine the levels of COX II mRNA. The top panel
corresponds to a representative autoradiography of the North-
ern membrane; the quanti¢cation of the bands is shown in the
bottom panel.
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bated the cells under known conditions to develop
resistance to the treatment, either in the absence or in
the presence of di¡erent concentrations of sodium
azide, an inhibitor of COX [14]. The concentrations
of NaN3 used (1 and 10 WM) did not a¡ect the via-
bility of the cells during 1 week (Fig. 3). Longer
exposure to sodium azide did not a¡ect the viability
and the cells grew until con£uence. Using both con-
centrations of NaN3, the number of resistant colo-
nies surviving the MTX treatment was markedly re-
duced. This decrease in the number of colonies was
dependent on the concentration of NaN3 (Fig. 4);
only 15% of the resistant clones remained if 10 WM
NaN3 was used. The decrease in resistance to MTX
in the presence of NaN3 was not due to a shift in the
curve of MTX cytotoxicity to lower concentrations
(Fig. 3). Furthermore, when cells were incubated
with MTX plus NaN3 in complete medium, which
provides the ¢nal products of DHFR activity, there
was no cytotoxicity.
Our observation that COX II overexpression takes
place in the early stages of the development of resis-
tant colonies to MTX is in keeping with current
knowledge about the processes leading to drug resis-
tance. Aside from the primary drug-target interac-
tion, as a consequence of the DNA damage pro-
duced, many chemotherapeutic agents, such as
amsacrine, camptothecin, cisplatin, etoposide, 5-£uo-
rouracil, MTX, melphalan and vincristine, can cause
apoptosis [15]. Thus, the e¡ect of an anticancer drug
is the result of the combination of the primary e¡ect
followed by the provoked induction of apoptosis
[16]. Therefore, if apoptosis is decreased or avoided,
for instance by p53 mutation or by an increased
Bcl2/Bax ratio, a certain number of cells survive
and become resistant to the drug attack. It has
been reported that avoidance of apoptosis can lead
to drug resistance, for example with cisplatin [17],
etoposide, arabinoside C, adriamycin and campto-
thecin [18]. Thus, the suppression of drug-induced
Fig. 4. E¡ect of sodium azide on the basal resistance to MTX.
CHO K1 cells (750 000) were incubated with the indicated con-
centrations of NaN3 for 7 days in the presence of 3U1037 M
MTX in selective 3GHT medium. Then, the medium was re-
placed and the MTX selection was maintained until the devel-
opment of resistant colonies. Results are expressed as the per-
centage of the number of colonies surviving selection with
MTX in the presence of NaN3 in relation to the number of re-
sistant colonies obtained with MTX alone.
Fig. 3. Cytotoxicity of sodium azide in CHO K1 cells (left). Three thousand CHO K1 cells were incubated with the indicated concen-
trations of NaN3 for 7 days in complete F-12 medium. The surviving colonies were ¢xed, stained with crystal violet and counted. Re-
sults are expressed as percent of cell survival in relation to the control in the absence of NaN3. E¡ect of sodium azide on MTX cyto-
toxicity (right). Three thousand CHO K1 cells were incubated with the indicated concentrations of MTX in selective 3GHT medium,
in the absence (¢lled squares) or in the presence of 1 WM (open squares) or 10 WM (open circles) NaN3 for 7 days. Results are ex-
pressed as percent of cell survival in relation to the control in the absence of MTX.
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apoptosis in tumor cells is now thought to be a
mechanism of pleiotropic drug resistance [16,19].
A variety of key events in apoptosis focuses on
mitochondria, including the release of caspase acti-
vators, such as cytochrome c, changes in electron
transport, loss of mitochondrial transmembrane po-
tential, altered cellular oxidation-reduction, and par-
ticipation of pro- and antiapoptotic Bcl-2 family pro-
teins [20].
Cytochrome c oxidase has been reported to be
essential for mitochondrial respiration, and its activ-
ity is also linked to apoptosis. It has been described
that in the apoptotic process induced by the over-
expression of Bax, there is a decrease in the amount
of COX complex [21]. Moreover, the transcription of
a TNF-K-induced antisense RNA directed toward
mitochondrial COX provoked cell death, whereas
the overexpression of COX suppressed apoptosis in-
duced by TNF-K [22].
Mitochondrial alterations have been associated
with resistance to the chemotherapeutic agent cispla-
tin. Zinkewich-Peotti and Andrews suggested that
the energy-producing role of mitochondria has an
in£uence on cisplatin resistance and demonstrated
that the reduction in mitochondrial membrane po-
tential was correlated with restored cisplatin sensitiv-
ity in previously resistant cells [23].
In the case of MTX, this drug causes apoptosis
[24^26] and also produces a decrease in mitochon-
drial respiration [27] and mitochondrial membrane
potential [28]. The increase in COX activity observed
upon MTX incubation could be a compensating
mechanism to restore the decrease in mitochondrial
activity, thus also reducing the apoptotic process that
could contribute to the appearance of MTX resis-
tance. The fact that inhibition of COX activity with
NaN3 decreases the frequency of resistance to MTX
argues in favor of the involvement of a COX over-
expression mechanism during the development of re-
sistance.
In summary, we report that COX II is overex-
pressed during the process of development of resis-
tance to MTX, and that inhibition of COX activity
leads to a decrease in the number of colonies resis-
tant to this drug. Therefore, these data support the
possibility of testing non-toxic concentrations of
NaN3, together with MTX, as a resistance modula-
tor in chemotherapy.
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